FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (110)CARES Phase III clinical programme did not meet primary endpoint in overall light chain amyloidosis population
Preheader (150)CARES Phase III clinical programme did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as p
Arial
Text Analysis
Body Words165
Subject Words16
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px822 px
X-Spam Score-0.5
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEarly Morning
